Schrödinger Appoints Veteran Biotech Industry Leader Dr. Rosana Kapeller to Board of Directors
Schrödinger, a privately held company revolutionizing drug discovery and materials design through advanced molecular simulations, today announced the appointment of veteran biotech leader Rosana Kapeller, M.D., Ph.D., to its board of directors.
“I am delighted and honored to join Schrödinger during such a pivotal time in the company’s growth,” said Dr. Kapeller. “I look forward to working with the team to help leverage their computational platform to expand their software business and build an exciting pipeline of novel therapeutics.”
Dr. Kapeller brings over two decades of biotech leadership experience and is deeply familiar with Schrödinger’s platform, having spent eight years in an executive role at Nimbus Therapeutics, a computation-driven drug discovery company co-founded by Atlas Venture and Schrödinger. As founding chief scientific officer of Nimbus, Dr. Kapeller led an interdisciplinary team that advanced multiple promising programs by applyingSchrödinger’s computational technologies to the design and development of novel therapeutics. Dr. Kapeller currently serves as the first entrepreneur-in-residence focused on life sciences at GV (formerly Google Ventures). GV invested in Schrödinger as part of an $85 million funding round announced earlier this month.
At GV, Dr. Kapeller focuses on the intersection of therapeutics and machine learning. Prior to her time at Nimbus, Dr. Kapeller worked as vice president of research at Aileron Therapeutics. She started her career as a scientist at Millennium Pharmaceuticals, where she advanced through positions of increasing responsibility to director. Dr. Kapeller has served as an adviser to Atlas Venture and a consultant to Third Rock Ventures and sits on the board of Cedilla Therapeutics. She holds a doctorate degree in molecular and cellular physiology from Tufts University and a medical degree from Universidade do Estado do Rio de Janeiro in Brazil.
“Rosana is an invaluable addition to our board, given her extensive background and deep expertise in drug discovery,” said Ramy Farid, Ph.D., Schrödinger’s CEO. “We are excited to work with her as we continue to invest in our computational platform, grow our software business, and progress our drug discovery programs.”
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schrödinger has a growing pipeline of early-stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. In addition, the company has deep partnerships and collaborations in such fields as biotechnology, pharmaceuticals, chemicals, and electronics. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Founded in 1990, Schrödinger has nearly 400 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005077/en/